Generate Biomedicines Inc.
GENB | NASDAQ
$13.38
-$1.08 (-7.47%)
Nov 2, 2026, 2:30 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Revenue | 6.31M | 7.22M |
Cost of Revenue | n/a | 3.27M |
Gross Profit | 6.31M | 3.95M |
Operating Income | -71.61M | -64.11M |
Interest Income | 4.63M | 2.91M |
Pretax Income | -67.2M | -61.69M |
Net Income | -67.26M | -61.45M |
Selling & General & Admin | 13.6M | 13.5M |
Research & Development | 64.33M | 54.56M |
Other Expenses | n/a | n/a |
Operating Expenses | 77.93M | 68.06M |
Interest Expense | 155K | 182K |
Selling & Marketing Expenses | n/a | n/a |
Cost & Expenses | 77.93M | 71.34M |
Income Tax Expense | 53K | 28K |
Shares Outstanding (Basic) | 128.24M | 128.19M |
Shares Outstanding (Diluted) | 128.24M | 128.19M |
EPS (Basic) | -0.52 | -0.54 |
EPS (Diluted) | -0.52 | -0.54 |
EBITDA | -63.82M | -60.84M |
EBIT | -67.05M | -64.11M |
Depreciation & Amortization | 3.22M | 3.27M |
Add to Watchlist
Select watchlists to add or remove GENB